nevirapine / Generic mfg. - LARVOL DELTA

Pre-treatment HIV-1 drug resistance spectrum and molecular transmission network characteristics in Zhejiang Province, 2023: implications for targeted control of drug-resistant HIV transmission. (PubMed, J Antimicrob Chemother) - "In this study, PDR cases in Zhejiang were dominated by NNRTI resistance with substantial regional clustering, indicating putative transmission networks. Scaled-up standardized PDR surveillance, optimized first-line ART regimens and cluster-targeted interventions are urgently needed to curb resistant HIV-1 transmission and inform national HIV drug resistance policy."

Journal • Human Immunodeficiency Virus • Infectious Disease

Rapid quantitative determination of zidovudine, lamivudine and nevirapine drugs in pharmaceutical tablets by stability-indicating monolithic liquid chromatography: validation, greenness, blueness and whiteness studies. (PubMed, J Chromatogr Sci) - "In addition, the greenness assessment, the holistic overall evaluation and the practicality check using the novel Analytical GREEnness Metric Approach and Software (AGREE) calculator, the RGB-12 model and Blue Applicability Grade Index (BAGI), respectively, were performed. The results demonstrated the environmental friendliness (AGREE), practicality (BAGI) and holistic sustainability profile (RGB-12 model) of the proposed method."

Journal

Association between infant post-natal prophylaxis regimens and pretreatment HIV drug resistance in infected infants. (PubMed, Front Epidemiol) - "We aimed to assess how different post-natal prophylaxis (PNP) strategies; nevirapine (NVP) alone vs zidovudine (ZDV) alone vs dual NVP + ZDV influenced NRTI resistance prevalence...Dual-drug prophylaxis was associated with a low prevalence of NRTI resistance compared to single-drug PNP. Our findings highlight the need for further research on combination prophylactic strategies in minimizing the emergence of drug resistance in this population."

Journal • Human Immunodeficiency Virus • Infectious Disease

Targeted point-of-care HIV testing at birth for newborns at high risk of vertical transmission in Botswana: a prospective cohort study. (PubMed, Lancet HIV) - "Near-point-of-care HIV testing at birth for high-risk newborns can identify the majority of HIV transmissions in early life. Simplified post-exposure prophylaxis may be appropriate in the setting of available maternal ART, even among infants at high risk."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

Drug-Associated Vanishing Bile Duct Syndrome: Screening for Potential Pharmaceutical Triggers Using the WHO Pharmacovigilance Database. (PubMed, Life (Basel)) - "Among these single-agent reports, 22 drugs demonstrated a positive IC0.25 signal, of which nevirapine, dapsone and azithromycin showed the strongest disproportionality signal. Only one of these agents (carbamazepine) explicitly labelled VBDS as an adverse event. These findings are based on spontaneous reporting data: disproportionality analysis is a hypothesis-generating signal-detection method that does not establish causality and requires further validation. This study expands the current understanding of drug-induced VBDS by reinforcing the associations with known drugs and generating pharmacovigilance signals for new potential VBDS triggers across several drug categories."

Adverse events • Journal • Cholestasis • Hepatology • Liver Failure

Association between initial antiretroviral therapy regimens and virological outcomes in HIV-infected individuals in Taizhou, Zhejiang Province, 2006-2025 (PubMed, Zhonghua Liu Xing Bing Xue Za Zhi) - "Apart from the two nucleotide reverse transcriptase inhibitors backbone drugs, the proportions of selecting efavirenz (EFV), nevirapine (NVP), lopinavir/ritonavir (LPV/r), dolutegravir (DTG), and other drugs as the third drug were 80.22% (2 976/3 710), 15.12% (561/3 710), 1.32% (49/3 710), 1.08% (40/3 710), and 2.26% (84/3 710) respectively-205 individuals (5.53%) with virological failure. After adjusting for the educational level of the study subjects, initial CD4+T lymphocyte counts, initial viral load, time interval from diagnosis to ART initiation, and the year of ART initiation, the risk of virological failure in the NVP group was 4.93 times that of the [integrase inhibitors/protease inhibitors(INSTI/PI)] group (95%CI: 1.73-14.05), and 2.72 times that of the EFV group (95%CI: 1.92-3.85). Among HIV-infected individuals in Taizhou who received NVP-based initial ART regimens between 2006 and 2025, the risk of virological failure was higher than among those who..."

Journal • Human Immunodeficiency Virus • Infectious Disease • CD4

Quenched fluorometric analysis of nevirapine and 4-nitrophenol in S,N-doped carbon dots derived from avocado seeds. (PubMed, Anal Methods) - "These quantitative methods for NVP or 4-NP demonstrated acceptable recoveries (88-103%) in spiked river water samples. Thus, the S,N-FCDs can be used for the quantitative detection of these two analytes down to ppb levels in samples where the two analytes do not coexist, with high accuracy, sensitivity, and selectivity, and can be applied to complex environmental samples."

Journal

Quantum dot (QD)-based silicon as an efficient catalyst for the one-pot synthesis of polynuclear acridines: molecular docking investigation of putative anti-tubercular and anti-HIV drug candidates. (PubMed, RSC Adv) - "For HIV-1 integrase, compounds 4d, 4l, and 4n showed superior binding affinities (-5.42, -5.32, and -5.32 kcal mol-1, respectively) compared to dolutegravir (-5.26 kcal mol-1) and nevirapine (-4.60 kcal mol-1), suggesting potential integrase inhibitory activity. Overall, the molecular docking results suggest that acridine derivatives, particularly 4d, 4l, and 4n, may serve as promising lead compounds for the development of anti-HIV and anti-tubercular agents. However, these findings are based solely on computational predictions and require further experimental validation through appropriate in vitro and in vivo biological studies."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Hepatic Responses as Potential Biomarkers of Idiosyncratic Drug Reaction Risk. (PubMed, Toxicol Sci) - "We had previously shown that clozapine and nevirapine produce a marked innate immune response in rodents. We sought to extend these studies to additional drugs that cause IDRs; namely, amodiaquine, carbamazepine, isoniazid, and ximelagatran...There is evidence that ximelagatran can directly activate macrophages, and it is plausible that isoniazid can also directly activate macrophages. It is likely that changes in hepatic mRNA consistent with a stress/innate immune response would represent biomarkers of iDILI risk; however, some drugs may directly activate macrophages without the need of factors released from the liver."

Biomarker • Journal • Hepatology • Liver Failure • DUSP1 • GADD45B • GDF15

National cross-sectional survey on acquired HIV drug resistance in Haiti in 2023: warnings resistance to dolutegravir (AIDS 2026) - "3.77% of HIVs were resistant to dolutegravir and bictegravir, 4.4% to cabotegravir, 4.72% to raltegravir, and 5.03% to elvitegravir. Additionally, 15.19% of the viral strains were resistant to abacavir, 13.92% to lamivudine and emtricitabine, 6.65% to zidovudine, 8.23% to stavudine and didanosine, and 4.13% to tenofovir...Furthermore, some HIVs strains developed resistance against efavirenz (49.37%), nevirapine (50%), Rilpivirine (20.25%), Etravirine (12.66%), and doravirine (3.61%). Finally, HIV genome resistance was 0.63% against atazanavir/ritonavir and indinavir/ritonavir, 0.95% against lopinavir/ritonavir and 0.32% against darunavir/ritonavir. HIV acquired pharmacoresistance is moderate in Haiti and requires innovating adapted strategy for preventing its development, its transmission, and for protecting PLHIV health, while emphasizing on children and male individuals."

Human Immunodeficiency Virus • Infectious Disease • Respiratory Diseases

Incidence of mutational patterns affecting doravirine or/and rilpivirine in people living with HIV and previous failure with NNRTIs efavirenz or nevirapine (AIDS 2026) - "BACKGROUND: The growing use of new non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as doravirine (DOR) or long-acting rilpivirine (RPV) makes necessary to evaluate the impact of previous failure to NNRTIs. Our results confirm that doravirine resistance in NNRTI-failing PLWH is lower than resistance to other NNRTIs currently used. However, these data suggest considering carefully genotypic resistance test results before the use of RPV or DOR in the clinical setting in those PLWH with previous failure to NNRTIs."

Human Immunodeficiency Virus • Infectious Disease • CD4

Resistance to etravirine and doravine in experienced PLHIV in Mexico. Impact on salvage treatment (AIDS 2026) - "BACKGROUND: Doravirine (DOR) and Etravirine (ETV) are the only NNRTIs indicated in people living with HIV (PLHIV) after virologic failure (VF) to first-generation NNRTIs as Efavirenz and Nevirapine. In our study, resistance to ETR in adult PLHIV who experienced at least two treatment failures in Mexico, was lower than to DOR. HLR was uncommon specially with respect to total sample, but higher (almost double) to DOR. Resistance prevalence could be higher, as most of the genotypes were performed without the NNRTI drug pressure."

Human Immunodeficiency Virus • Infectious Disease

Antiretroviral treatment trajectories and post-listing outcomes in people living with HIV or AIDS listed for kidney or liver transplantation: a national cohort study in Brazil (AIDS 2026) - "Longer cumulative exposure to multiple antiretrovirals—including lamivudine, zidovudine, efavirenz, darunavir, dolutegravir, lopinavir, nevirapine, ritonavir, and tenofovir disoproxil fumarate—was consistently associated with lower post-listing mortality (Spearman ? In this nationwide study, longer cumulative exposure to widely used antiretrovirals was associated with lower mortality after listing, even for drugs traditionally described as hepatotoxic or nephrotoxic. This suggests, in this context, cumulative ART exposure primarily reflects sustained engagement in care, rather than a direct pharmacological toxicity effect on mortality. This first national linkage of transplant and HIV information systems provides evidence to inform the integration of HIV care and transplant services, and supports future evaluations of equity and outcomes among aging populations living with HIV."

Human Immunodeficiency Virus • Infectious Disease • Solid Organ Transplantation • Transplantation

HIV in the triple elimination strategy of mother to child transmission (Trimom Study): an overview of transmission and post-partum follow up in The Gambia (AIDS 2026) - "All babies were started on Nevirapine syrup and the first infant screening results at 6-8 weeks were received for 46 babies... A simplified integrated triple elimination strategy is feasible in Sub-Saharan African countries. ART for mothers and ARV prophylaxis adherence with follow up in babies can end vertical transmission. Infant screening still requires strengthening."

Clinical • Late-breaking abstract • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Optimizing and strengthening the HIV response in the province of Buenos Aires: a management model in Argentina's most populated province (AIDS 2026) - " Under these premises, the PBA currently features: 704 testing centers covering 113 municipalities; 151 healthcare facilities for adult HIV medical care, including PrEP; 83 facilities offering PEP with a 24-hour emergency telephone line for access difficulties; 125 facilities for the medical care of pregnant people living with HIV and perinatally exposed infants; 41 facilities for pediatric HIV care; 75 facilities for VH care; a decentralized laboratory network for molecular biology, cytometry, and high-cost testing; and the public production of dispersible Nevirapine to address regional shortages for the treatment of premature perinatally exposed infants... This development confirms the necessity of an active State with robust public health policies focused on the right to health, quality of care, and management efficiency."

Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation

Programmatic gaps under option B+: factors associated with residual vertical HIV transmission in Malawi, 2020–2024 (AIDS 2026) - "There was no significant difference in transmission rates between infants who received nevirapine alone and those who received a combination of nevirapine, zidovudine, and lamivudine as prophylaxis... In our study, vertical transmission was strongly associated with lack of ART at delivery and unsuppressed maternal viral load. Maternal viral load coverage was also suboptimal. These findings suggest potential missed opportunities along the eVT care cascade."

Human Immunodeficiency Virus • Infectious Disease

Do newly optimized HIV drug regimens work better for young people living with HIV? Evidence from Uganda (AIDS 2026) - "Regimen transitions were classified into 11 groups, including Abacavir (ABC)/Zidovudine (AZT) to DTG, DTG to DTG, Efavirenz (EFV) or Nevirapine (NVP) to DTG, EFV or NVP to Protease Inhibitor(PI), EFV or NVP to PI/DTG, and PI to DTG, PI, or PI/DTG. ART optimization at MUgH enhanced viral suppression, particularly with dolutegravir-based regimens, while protease inhibitor transitions showed slower improvement. Persistent viremia and frequent respiratory events highlight the need for vigilant monitoring, adherence evaluation and support, and timely interventions to sustain long-term treatment success among children and adolescents living with HIV."

Human Immunodeficiency Virus • Infectious Disease

Low-levels of breakthrough infection and drug resistance among key populations receiving pre-exposure prophylaxis in sub-Saharan Africa: systematic review and meta-analysis (AIDS 2026) - "Interestingly, DRMs reported were M184VI (1/2; specific to Emtricitabine or Lamivudine) and K103N (1/2; specific to Efavirenz and Nevirapine). The low levels of breakthrough infection and HIVDR after PrEP-failure underscore the high benefits of large-scale implementation of PrEP among KP in SSA. Thus, accelerating efforts toward HIV elimination especially in KP requires reinforcing adherence, introducing injectable PrEP, and selecting optimal ART-regimens (guided by HIVDR profiling) following HIV acquisition. PROSPERO registration N°CRD42023463862 Keywords: HIV-1; Key population; Pre-exposure prophylaxis; Drug resistance mutations; Sub-Saharan Africa"

Retrospective data • Review • Human Immunodeficiency Virus • Infectious Disease

Cross-resistance to second-generation INSTI after raltegravir-based regimen failure in children living with HIV under 14 years of age (AIDS 2026) - "Pediatric formulations of protease inhibitors are not available, the supply of nevirapine oral solution is intermittent, and raltegravir is the only INSTI available in a pediatric formulation for children weighing <20 kg. In this group of children who experienced failure on a raltegravir-based regimen, cross-resistance to second-generation integrase inhibitors was high, reaching approximately 77%, with 44% of cases showing high-level or intermediate-level resistance. Raltegravir is the drug of choice for the management of children living with HIV under 12 years of age in Colombia; however, it is not recommended in international pediatric treatment guidelines, except for use in infants younger than 30 days, with a recommendation to switch to dolutegravir after this age. In Colombia, the lack of access to second-generation INSTIs for children weighing less than 20 kg has negatively affected the achievement of virologic control, allowed the development of resistance at..."

Clinical • Human Immunodeficiency Virus • Infectious Disease

Dolutegravir coverage and viral suppression among adolescents and young adults living with HIV in Africa: findings from nine nationally-representative surveys, 2019-2023 (AIDS 2026) - "ALWH aged 15-24 years (sample n = 1827) were categorized into one of three mutually exclusive treatment groups: DTG-based regimen, non-DTG-based regimens (Efavirenz, Atazanavir/ritonavir, Nevirapine, Lopinavir/ritonavir); and not currently on any treatment. DTG-based regimen is superior to other ART options in achieving viral load suppression in adolescents. To reach global targets, programs should continue prioritizing DTG-based ART while intensifying efforts to initiate treatment for all individuals currently not on ART. Additionally, population-based viral suppression for ALWH on DTG remains lower than observed in clinical trials."

Clinical • Human Immunodeficiency Virus • Infectious Disease

Drug-Drug Interaction Between Praziquantel and Nevirapine in HIV-Schistosomiasis Co-infection: A Pharmacokinetic case report. (PubMed, J Travel Med) - No abstract available

Journal • PK/PD data • Human Immunodeficiency Virus • Infectious Disease

A novel design using a virtual control group to evaluate non-inferiority of nevirapine and lamivudine dual maintenance in HIV therapy. (PubMed, PLoS One) - "Simplification to NVP and 3TC was as effective as the ideal virtual control. However, the results of NVP and 3TC maintenance therapy are only applicable to people living with HIV who meet the study's inclusion and exclusion criteria. Virtual controls could improve research efficiency and warrant further evaluation."

Clinical • Head-to-Head • Journal • Human Immunodeficiency Virus • Infectious Disease

Geospatial analysis reveals similar HIV-1 drug resistance patterns among antiretroviral therapy-experienced children and adolescents (0-17 years) of South Africa. (PubMed, Commun Med (Lond)) - "Routine GRTs demonstrate high HIVDR prevalence among younger children, while ART susceptibility maps show overall uniformity with variations in certain regions, such as northern KwaZulu-Natal localities. GIS-linked real-time monitoring of HIVDR is crucial to assess the impact of the revised HIV-1 treatment guidelines for CALWH in South Africa."

Journal • Human Immunodeficiency Virus • Infectious Disease

Neonatal HIV prophylaxis is associated with accelerated presentation and clinical progression of MPV17-related mitochondrial neurohepatopathy. (PubMed, BMC Pediatr) - "Perinatal therapy with the nucleoside reverse transcriptase inhibitor zidovudine, a known mitochondrial toxin, was associated with accelerated clinical presentation and clinical course of MPV17 neurohepatopathy. Our findings suggest that less toxic antiretroviral therapy should be considered for perinatal HIV prophylaxis in HIV-exposed infants, particularly in our setting where there is a high carrier frequency of a single pathogenic MPV17 variant."

Journal • Developmental Disorders • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Liver Failure • Metabolic Disorders • Pain

Neonatal Lactic Acidosis Associated With Antiretroviral Exposure: A Case Report. (PubMed, Cureus) - "The patient was receiving HIV prophylaxis with lamivudine, zidovudine, and nevirapine...In coordination with the Infectious Disease team, the ART regimen was modified to raltegravir and lamivudine, resulting in metabolic improvement. This case underscores the importance of recognizing ART-related toxicity in neonates with progressive hyperlactatemia despite initially subtle clinical manifestations, prompting early treatment readjustment and close monitoring."

Journal • Cardiovascular • Human Immunodeficiency Virus • Infectious Disease • Metabolic Disorders